| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/16/2011 | EP2295467A1 Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof |
| 03/16/2011 | EP2295456A1 Albumin fusion proteins |
| 03/16/2011 | EP2295454A1 SLO2, a novel potassium channel protein from human brain |
| 03/16/2011 | EP2295442A2 Inhibitors of interleukin-1beta converting enzyme |
| 03/16/2011 | EP2295436A1 2-Phenyl-subsitituted Imidazotriazinones as Phosphodiesterase V inhibitors |
| 03/16/2011 | EP2295413A1 Indazole compounds useful as protein kinase inhibitors |
| 03/16/2011 | EP2295412A1 Indazole compounds useful as protein kinase inhibitors |
| 03/16/2011 | EP2295409A1 Fluoro substituted cycloalkanoindoles and their use as prostaglandin D2 receptor antagonists |
| 03/16/2011 | EP2295079A2 Method for treating inflammation |
| 03/16/2011 | EP2295078A2 Method for treating inflammation |
| 03/16/2011 | EP2295062A1 The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis |
| 03/16/2011 | EP2295060A2 Stabilization of hypoxia inducible factor (HIF) alpha |
| 03/16/2011 | EP2295059A2 Stabilization of hypoxia inducible factor (HIF) alpha |
| 03/16/2011 | EP2295057A1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| 03/16/2011 | EP2295055A2 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of using and compositions thereof |
| 03/16/2011 | EP2294918A1 Use of a ribonuclease of the T2 family having actin-binding activity for inhibiting and/or reversing proliferation |
| 03/16/2011 | EP2293801A1 Method for preventing corticosteroid usage |
| 03/16/2011 | EP2293795A1 Pharmaceutical combination |
| 03/16/2011 | EP1495018B3 Tricyclic thrombin receptor antagonists |
| 03/16/2011 | EP1448535B1 Benzamide and heteroarylamide as p2x7 receptor antagonists |
| 03/16/2011 | EP1383785B1 Recombinant tumor specific antibody and use thereof |
| 03/16/2011 | EP1344777B1 Imidazole derivatives, process for their preparation and their use |
| 03/16/2011 | EP1104281B1 Incorporation of exogenous lactic bacteria into the oral microflora |
| 03/16/2011 | CN1850067B In vivo oxygen-supply solution for injection, and its preparing method and use |
| 03/16/2011 | CN101985037A Applications of receptor for activated C-kinase 1 as target against tumor drug-resistance |
| 03/16/2011 | CN101984979A Disease toxin expelling juice |
| 03/16/2011 | CN101575335B Dehydrogenated silibinin substituted by meta-chlorobenzene formoxyl, preparation method and pharmaceutical applications thereof |
| 03/16/2011 | CN101491520B Local application medicine formulation |
| 03/16/2011 | CN101244099B Method for preparing valid target in gavel fruit vine fruit and application of the same |
| 03/15/2011 | US7906659 Carbocyclic and oxacarbocyclic fumaric acid oligomers |
| 03/15/2011 | US7906644 2,4-pyrimidinediamine compounds and their uses |
| 03/15/2011 | US7906629 Protease inhibitor conjugates and antibodies useful in immunoassay |
| 03/15/2011 | US7906616 Truncated DANCE, DANCE complex and method of using these |
| 03/15/2011 | US7906545 Prodrugs of CC-1065 analogs |
| 03/15/2011 | US7906523 retrovirus inhibor; anticarcinogenic, antidiabetic agent, immunosuppressant, autoimmune diseases; 2-{6-[3(R)-Amino-piperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-4-fluoro-benzonitrile; type 2 diabetes mellitus, impaired glucose tolerance, obesity, multiple sclerosis |
| 03/15/2011 | US7906491 Compounds for modulating the activity of exchange proteins directly activated by cAMP (Epacs) |
| 03/15/2011 | US7906150 Preparation derived from shark cartilage for treatment of diseases related to excessive PHF or excessive intracellular calcium |
| 03/15/2011 | US7906139 phosphatidylcholine, sphingomyelin, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl inositol, and cholesterol; for removal of extra-/intra- vascular fibrin clots/adhesions; for use during surgery; for treatment of otitis |
| 03/15/2011 | US7906128 Controlling parasites in animals by administerinng sodium channel activators |
| 03/15/2011 | CA2677910C The use of inhibitors of the renin-angiotensin system for the treatment of cardiovascular diseases |
| 03/15/2011 | CA2630665C Heterocyclic compound having inhibitory activity on 11-.beta.-hydroxysteroid dehydrogenase type i |
| 03/15/2011 | CA2494063C Inhibition of proliferation and infiltration of brain tumor cells caused by expression of ampa-type glutamate receptor subunit |
| 03/15/2011 | CA2480708C Method and dietary composition for improving fat digestibility |
| 03/15/2011 | CA2473910C Pyrimidine derivatives as rho-kinase inhibitors |
| 03/15/2011 | CA2471814C Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient |
| 03/15/2011 | CA2470583C Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes |
| 03/15/2011 | CA2468311C Benzothiazole derivatives |
| 03/15/2011 | CA2458318C Wortmannin analogs and methods of using same |
| 03/15/2011 | CA2458266C Substituted urea retinoid agonists ii |
| 03/15/2011 | CA2452005C Inhibition of apoptosis process and improvement of cell performance |
| 03/15/2011 | CA2451230C Eurotinones, and derivatives thereof, processes for preparing them, and their use |
| 03/15/2011 | CA2431160C Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 03/15/2011 | CA2426440C Quinazoline derivatives as kinase inhibitors |
| 03/15/2011 | CA2423568C Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same |
| 03/15/2011 | CA2415611C Biologically active macrolides, compositions, and uses thereof |
| 03/15/2011 | CA2406008C Composition exhibiting enhanced formulation stability and delivery of topical active ingredients |
| 03/15/2011 | CA2402038C Lpa receptor agonists and antagonists and methods of use |
| 03/15/2011 | CA2379575C Pharmaceutically active sulfonamide derivatives |
| 03/15/2011 | CA2360415C Benzimidazole vascular damaging agents |
| 03/15/2011 | CA2343009C Use of benzenesulfonyl(thio)ureas for the treatment and prophylaxis of dysfunctions of the autonomous nervous system and use of benzenesulfonyl(thio)ureas in combination with beta-receptor blockers |
| 03/15/2011 | CA2315117C Heterocyclic ether and thioether compounds useful in controlling chemical synaptic transmission |
| 03/15/2011 | CA2289119C Methods for treating inflammation and inflammatory diseases using padprt inhibitors |
| 03/15/2011 | CA2232191C Inhibition of tumor necrosis factor alpha |
| 03/10/2011 | WO2011028673A2 A composition for delaying cellular senescence |
| 03/10/2011 | WO2011027916A1 Therapeutic agent for allergic diseases |
| 03/10/2011 | WO2011027888A1 Diamide-phenyl derivative and pharmaceutically acceptable salt thereof |
| 03/10/2011 | WO2011027849A1 Heterocyclic compound |
| 03/10/2011 | WO2011027551A1 Hydrogen sulfide-producing enzyme inhibitor |
| 03/10/2011 | WO2011027344A2 Combination of vitamin e and beta-glycosphingolipids in compositions and methods for preventing and treating hepatic disorders |
| 03/10/2011 | WO2011026641A1 Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| 03/10/2011 | WO2011026536A1 Novel therapeutic concepts for treating fibromyalgia |
| 03/10/2011 | US20110060024 Modulators of ATP-Binding Cassette Transporters |
| 03/10/2011 | US20110060016 Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
| 03/10/2011 | US20110060014 Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents |
| 03/10/2011 | US20110059985 Novel formulation |
| 03/10/2011 | US20110059959 Novel multicyclic compounds and the use thereof |
| 03/10/2011 | US20110059935 Beta-LACTAMYL VASOPRESSIN V1a ANTAGONISTS |
| 03/10/2011 | US20110059906 Energy status of an individual by enhanced production of an endogenous fuel source |
| 03/10/2011 | US20110059896 Use of furin convertase inhibitors in the treatment of fibrosis and scarring |
| 03/10/2011 | US20110059890 Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas |
| 03/10/2011 | US20110059182 Spraying device and related method for cell aggregates and cell aggregate suspension thereof |
| 03/10/2011 | US20110059179 controlled delivery system that provides malodor management over a prolonged period of time |
| 03/10/2011 | US20110059167 Encapsulation of biologically active agents |
| 03/10/2011 | US20110059160 Methods and compositions for targeted gene modification |
| 03/10/2011 | US20110059120 Glucan-based vaccines |
| 03/10/2011 | US20110059117 Liquid Compositions Capable of Foaming and Including Active Agents, and Methods for Making or Developing Same |
| 03/10/2011 | US20110059080 Use of an anti-il6 antibody to decrease hepcidin in cancer patients |
| 03/10/2011 | US20110059066 PAKs as Modifiers of the CHK Pathway and Methods of Use |
| 03/10/2011 | US20110059056 Method for the Generation of Genetically Modified Vertebrate Precursor Lymphocytes and Use Thereof for the Production of Heterologous Binding Proteins |
| 03/10/2011 | DE102009039546A1 Neue therapeutische Konzepte für die Behandlung von Fibromyalgien New therapeutic approaches for the treatment of fibromyalgia |
| 03/10/2011 | CA2765421A1 Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| 03/09/2011 | EP2292734A1 Hematopoietic cells from human embryonic stem cells |
| 03/09/2011 | EP2292631A1 Regeneration of endogenous myocardial tissue by induction of neovascularization |
| 03/09/2011 | EP2292629A1 Method of isolating cytisine from biomaterial |
| 03/09/2011 | EP2292623A1 Acylated phthalocyanines |
| 03/09/2011 | EP2292614A1 Substituted pyrimidines as aurora kinase inhibitors |
| 03/09/2011 | EP2292610A1 Macrolides with VEGF transcription suppression activity |
| 03/09/2011 | EP2292596A2 CETP activity inhibitor |
| 03/09/2011 | EP2292595A1 Potassium channel modulators |
| 03/09/2011 | EP2292593A2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |